Returning Players: Original Applications That Are Back Before FDA After A “Complete Response” Letter
Novel products that could see approval in 2012 after addressing previous action letters.
You may also be interested in...
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Medical device regulations that were set in place by the US FDA in the 1990s are evolving with the emergence of digital-health products and their iterative nature, medtech consultant Jon Speer says. Check out his comment here.